Areva to provide University of Cincinnati lead-212 for cancer research

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Areva has signed a research agreement with the University of Cincinnati to provide the medical-grade isotope lead-212 to the university to conduct research on alpha radio-immunotherapy using this isotope to treat prostate cancer.

The company, headquartered in Bethesda, Md., is developing new processes to produce lead-212 and has planned to build a new medical isotope production facility in southern France.